Le livre est actuellement en rupture de stock
En savoir plus sur le livre
Duchenne muscular dystrophy, a rare genetic disorder, currently has only one authorized treatment: ataluren. However, its efficacy, financing, and availability vary across Europe and Spain, where it is not covered by public health systems, leaving affected children without access to treatment. This situation has sparked a significant debate encompassing ethical issues of equity and justice, alongside legal principles concerning the protection of minors, highlighting the complexities surrounding healthcare access for rare diseases.
Achat du livre
DUCHENNE DISEASE: COMPLEXITIES IN THE USE OF ATALUREN IN SPAIN., Pilar Pacheco López, María Antonia Meroño Saura, Miguel Ángel Carvajal Sánchez
- Langue
- Année de publication
- 2022
- product-detail.submit-box.info.binding
- (souple)
Nous vous informerons par e-mail dès que nous l’aurons retrouvé.
Modes de paiement
Personne n'a encore évalué .